Nasdaq

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...
Nasdaq

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

Cardiovascular disease remains a leading cause of mortality in both Canada and globally; the lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience ...
Baylor College of Medicine

Reverse Phase Protein Array Publications

Zhongcheng Shi, Michael Hoang Nguyen, Yuan Yao, Shixia Huang. High-Throughput Post-Translational Modification Analyses by Reverse Phase Protein Array. Protein Arrays: methods and applications. 2024 ...